Publications by authors named "Christine McLeod"
We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1).
View Article and Find Full Text PDFPhase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
Ther Adv Med Oncol
November 2024
Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies.
Objectives: This study presents the first results of ipilimumab-nivolumab in invasive mucinous or non-mucinous lepidic adenocarcinoma (invasive mucinous adenocarcinoma (IMA) or invasive non-mucinous lepidic adenocarcinomas (INLA), respectively) of the lung.
Design: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) is a prospective, open-label, multicenter (1016 US sites), multi-cohort phase II trial of ipilimumab (1 mg/kg intravenously (IV) every 6 weeks) plus nivolumab (240 mg IV every 2 weeks).
Article Synopsis
- The SWOG S1609 DART trial investigated the effectiveness of dual therapy with ipilimumab and nivolumab in patients with vulvar cancers, showing initial promising results.
- In this phase II clinical trial involving 16 patients, the objective response rate was 18.8%, with some patients exhibiting durable responses and stable disease.
- Adverse effects were common, including diarrhea and fatigue, with 25% of patients experiencing severe side effects, highlighting the need for ongoing studies to identify response and resistance markers.
Article Synopsis
- The study assesses the effectiveness of a dual checkpoint inhibition therapy (ipilimumab and nivolumab) on advanced non-epithelial ovarian cancers (NEOCs) in patients who have no other effective treatments available.
- In a clinical trial involving 17 patients, the therapy showed a 25% overall response rate in those with granulosa cell tumors, with some patients experiencing significant progression-free survival and overall survival benefits.
- However, the therapy had serious side effects, leading to treatment discontinuation in 18% of participants and no positive responses noted in carcinosarcoma cases.
Article Synopsis
- Dual inhibition using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) was tested on patients with desmoid tumors in a phase II clinical trial to assess efficacy and safety in treating these rare solid tumors.
- The study involved 16 patients, with an overall response rate (ORR) of 18.8%, and a clinical benefit rate (CBR) of 62.5%, indicating decent stability and response to treatment over an average of 19.4 months of progression-free survival (PFS).
- Adverse events were common, with fatigue, nausea, and hypothyroidism reported, highlighting the need for careful monitoring during treatment.
Objectives: Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.
Design/setting: A prospective, phase 2 clinical trial of ipilimumab plus nivolumab was conducted by the SWOG Early Therapeutics and Rare Cancers Committee for multiple rare tumor cohorts across >1,000 National Clinical Trial Network sites.
Background: The authors previously reported the results of the nonpancreatic neuroendocrine neoplasm cohort of the SWOG S1609 DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial, which permitted all histologic grades and had a 44% overall response rate (ORR) among patients with high-grade disease. Here they sought to validate their findings in a dedicated prospective cohort of high-grade neuroendocrine neoplasms within S1609.
Methods: A prospective, open-label, multicenter, phase 2 clinical trial of ipilimumab plus nivolumab was conducted across multiple rare tumor cohorts.
Purpose: Immune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Patients And Methods: We performed a prospective, open-label, multicenter phase II clinical trial of ipilimumab plus nivolumab across multiple rare tumor cohorts, with the (nonpancreatic) neuroendocrine cohort reported here.